Aaron Kantoff

Aaron Kantoff is an accomplished board member and entrepreneur with extensive experience in the biotechnology sector. Currently serving as a board member for The Lustgarten Foundation and Tourmaline Bio, Kantoff focuses on advancements in pancreatic cancer treatment and the development of transformative medicines for immune and inflammatory diseases, respectively. As a co-founder and managing partner at Scion Life Sciences and a founding board member at RayzeBio, which was acquired by Bristol Myers Squibb, Kantoff has played a significant role in targeted therapeutics. Previous board roles include Centessa Pharmaceuticals, Akero Therapeutics, Corvidia Therapeutics, and Elstar Therapeutics, demonstrating a strong commitment to innovation in healthcare. Kantoff began career involvement in venture capital as a partner at Apple Tree Partners and holds a B.S. in Finance and International Business from New York University's Leonard N. Stern School of Business.